Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Real-Time Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
00867 CMS
RTNominal unchange11.340 0.000 (0.000%)
Others

06/11/2019 15:55

CMS (00867) signs products license agreement

[ET Net News Agency, 6 November 2019] China Medical System Holdings Limited (00867)
said the group through its wholly-owned subsidiary signed a license agreement with Sun
Pharma Advanced Research Company Ltd. (SPARC) for five innovative products.
According to the Agreement, the group through its wholly-owned subsidiary will gain an
exclusive license with the right to grant sublicenses under SPARC's intellectual property
rights and regulatory documentation to develop and commercialise the products in Greater
China.
The initial term of the agreement shall be 20 years from the first commercial sale of
the products in the territory and may be extended for additional 3 years increments if the
wholly owned subsidiary of the group meets certain conditions defined in the agreement.
(RC)

Remark: Real time quote last updated: 16/12/2019 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2019 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.